#AS­CO22: Gilead’s Trodelvy shows slim ben­e­fit in com­mon form of breast can­cer

In March, Gilead drew ire from an­a­lysts for re­leas­ing an up­beat Q&A with­out any hard da­ta for its lat­est Trodelvy tri­al, which put in­to ques­tion whether the big biotech’s drug would be ef­fec­tive in one of the most com­mon forms of breast can­cer.

Now, the da­ta are fi­nal­ly here, show­ing that Trodelvy slight­ly out­did stan­dard care in an on­go­ing Phase III study with over 500 pa­tients who have HR+/HER2- metasta­t­ic breast can­cer. All of the pa­tients had al­ready been treat­ed with en­docrine ther­a­py and more than half had three or more pre­vi­ous chemother­a­py reg­i­mens.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.